J. Rochon

发表

Drug-Induced Liver Injury Network (DILIN) Prospective Study

R. Fontana, P. Watkins, H. Bonkovsky, 2009, Drug safety.

Analyzing bivariate repeated measures for discrete and continuous outcome variables.

J Rochon, J. Rochon, 1996, Biometrics.

Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases.

R. Fontana, H. Bonkovsky, T. Davern, 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Clinical and histopathologic features of fluoroquinolone-induced liver injury.

H. Conjeevaram, J. Rochon, J. Freston, 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Using a Serial Marker to Predict a Repeated Measures Outcome in a Cohort Study

J. Rochon, 2003, Journal of biopharmaceutical statistics.

Drug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct

R. Fontana, P. Watkins, H. Bonkovsky, 2013 .

Book Review: Sample size calculations in clinical research

J. Rochon, 2005 .

Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection.

J. Rochon, A. Jevnikar, C. Stiller, 1993, Journal of immunology.

Sample Size Calculations for Controlled Clinical Trials Using Generalized Estimating Equations (GEE)

I. König, J. Rochon, G. Dahmen, 2004, Methods of Information in Medicine.

Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection.

J. Rochon, A. Jevnikar, C. Stiller, 1993, Transplantation proceedings.

Issues in Adjusting for Covariates Arising Postrandomization in Clinical Trials

James Rochon, J. Rochon, 1999 .

Survival of cadaveric renal transplant grafts from young donors and in young recipients

J. Rochon, G. Arbus, D. Thompson, 2004, Pediatric Nephrology.

Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.

R. Fontana, P. Watkins, H. Bonkovsky, 2008, Gastroenterology.

Cyclosporine Neoral in liver transplant recipients.

J. Rochon, G. Levy, S. Asfar, 1994, Transplantation proceedings.

Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs

K. Shianna, D. Ge, D. Goldstein, 2012, Pharmacogenetics and genomics.

Causality assessment in drug‐induced liver injury using a structured expert opinion process: Comparison to the Roussel‐Uclaf causality assessment method

R. Fontana, N. Chalasani, J. Rochon, 2010, Hepatology.

Analysis of risk factors influencing the development of severe dizziness in patients with vestibular schwannomas in the immediate postoperative phase

J. Rochon, G. Feigl, A. Brawanski, 2011, Clinical Neurology and Neurosurgery.

Radiologic Management of Lower Gastrointestinal Tract Bleeding

Parag, Patel, Š., 2015 .

A statistical model for the "N-of-1" study.

J. Rochon, 1990, Journal of clinical epidemiology.

Serum proteomic profiling in patients with drug‐induced liver injury

R. Fontana, P. Watkins, H. Bonkovsky, 2012, Alimentary Pharmacology and Therapeutics.

Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment.

L. Schneider, R. Heaton, J. Rochon, 1998, Archives of neurology.

ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis

D. Arnold, J. Rochon, M. Freedman, 2017, Multiple sclerosis.

Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug‐induced liver injury

R. Fontana, P. Watkins, T. Davern, 2008, Hepatology.

Statistical Considerations for the Design of the Optimal Clinical Trial

J. Rochon, G. Doig, 1995 .

The application of the GSK method to the determination of minimum sample sizes.

J. Rochon, 1989, Biometrics.

An early ‘clinical trial’ as a teaching exercise: the Book of Daniel 1.1–15 (1.1–20)

J. Rochon, Truls Østbye, 1993, Medical education.

Using a Serial Marker to Predict a Repeated Measures Outcome in a Cohort Design—Results of a Simulation Study

J. Rochon, James Rochon Ph.D., 2004, Journal of biopharmaceutical statistics.

Accounting for Covariates Observed Post Randomization for Discrete and Continuous Repeated Measures Data

J. Rochon, 1996 .

Application of GEE procedures for sample size calculations in repeated measures experiments.

J Rochon, J. Rochon, 1997, Statistics in medicine.

Supplementing the Intent-to-Treat Analysis: Accounting for Covariates Observed Postrandomization in Clinical Trials

J. Rochon, 1995 .

ARMA Covariance Structures with Time Heteroscedasticity for Repeated Measures Experiments

James Rochon, J. Rochon, 1992 .

Maximum likelihood estimation for incomplete repeated-measures experiments under an ARMA covariance structure.

R W Helms, J Rochon, J. Rochon, 1989, Biometrics.

Inference from the incomplete longitudinal design under an ARMA covariance structure

J. Rochon, 1985 .

Sample size calculations for two-group repeated-measures experiments

James Rochon, J. Rochon, 1991 .

Mixed-Effect Models to Assess Consistency and Reliability Across Multiple Evaluations

J. Rochon, T. Kao, Yvonne H Sparling, 2003, Journal of biopharmaceutical statistics.

Pharmacokinetics of a New Oral Formulation of Cyclosporine in Liver Transplant Recipients

J. Rochon, G. Levy, S. Asfar, 1995, Therapeutic drug monitoring.

[Portal hypertension and hemorrhoids. Cause effect relationship?].

J. Rochon, H. Michel, P. Bories, 1988, Gastroentérologie Clinique et Biologique.

Application of the marginal structural model to account for suboptimal adherence in a randomized controlled trial

James Rochon, Manjushri Bhapkar, Carl F. Pieper, 2016, Contemporary clinical trials communications.

Analyzing the number of "rejection episodes" in renal transplant studies.

J. Rochon, C. Cardella, M. Aprile, 1992, Transplantation.

Characteristics of Patients with Idiosyncratic Drug Induced Liver Injury (DILI) Who Receive Systemic Corticosteroids: Initial Results from the U.S. DILI Network Prospective Study

R. Fontana, P. Watkins, H. Bonkovsky, 2008 .

Application of GEE procedures for sample size calculations in repeated measures experiments

James Rochon, J. Rochon, 1998 .

Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators.

A. Laupacis, J. Rochon, B. Feagan, 1994, The New England journal of medicine.

Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group.

J. Rochon, B. Feagan, R. Fedorak, 1994, Gastroenterology.

Serum proteomic profiling in patients with drug‐induced liver injury

R. Fontana, P. Watkins, H. Bonkovsky, 2012, Alimentary pharmacology & therapeutics.

ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis

D. Arnold, J. Rochon, M. Freedman, 2017, Multiple sclerosis.

A methodology for analysing a repeated measures and survival outcome simultaneously

J. Rochon, B. Gillespie, 2001, Statistics in medicine.

Drug-Induced Liver Injury Network (DILIN) Prospective Study

R. Fontana, P. Watkins, H. Bonkovsky, 2009, Drug safety.

Interaction and intervention modeling: predicting and extrapolating the impact of multiple interventions.

R. Riegelman, J. Rochon, A. El-Mohandes, 2002, Annals of epidemiology.